Welcome to our dedicated page for iRhythm Holdings SEC filings (Ticker: IRTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
iRhythm Holdings, Inc. filings document the public-company reporting of a digital health care business centered on ambulatory cardiac monitoring. Recent Form 8-K disclosures report operating results, financial condition, guidance-related exhibits, Regulation FD materials, material agreements, executive compensation policy changes, board appointments, and changes in the independent registered public accounting firm.
Proxy materials cover director elections, board and committee structure, executive compensation, equity awards, and stockholder voting matters. The filing record also documents the completed holding-company reorganization under which iRhythm Holdings became successor registrant to iRhythm Technologies, including common-stock continuity and predecessor registration-termination records.
iRhythm Holdings, Inc. executive Minang Turakhia reported acquiring 137 shares of common stock, bringing his direct holdings to 55,043 shares. The shares were acquired through the company’s 2016 Employee Stock Purchase Plan for the purchase period from December 1, 2025 through May 31, 2026 and are reported as an exempt award transaction under Rule 16b-3.
iRhythm Holdings, Inc. executive Chad Patterson reported acquiring 177 shares of common stock at $96.815 per share. The shares were purchased through the company’s 2016 Employee Stock Purchase Plan for the period from December 1, 2025 through May 31, 2026.
After this plan-related acquisition, Patterson directly holds 58,341 shares of iRhythm common stock. The filing notes that this transaction is exempt from Section 16(b) under Rule 16b-3 and is being reported on a voluntary basis.
iRhythm Holdings EVP Sean Clinton Freeman acquired additional company stock through a compensation plan. He received 273 shares of common stock on May 29, 2026 at $96.815 per share, increasing his direct holdings to 14,559 shares. The footnote explains this was a voluntary report of shares acquired under iRhythm’s 2016 Employee Stock Purchase Plan for the purchase period from December 1, 2025 through May 31, 2026, and notes the transaction is exempt from Section 16(b) under Rule 16b-3, indicating it is a routine, plan-based acquisition rather than an open-market trade.
iRhythm Holdings, Inc. President and CEO Quentin S. Blackford reported an acquisition of 178 shares of common stock at $96.815 per share. The shares were acquired under the company’s 2016 Employee Stock Purchase Plan for the purchase period from December 1, 2025 through May 31, 2026, in a transaction exempt from Section 16(b) under Rule 16b-3. Following this Plan purchase, he holds 204,333 shares of common stock directly.
iRhythm Holdings director Cathleen Noel Bairey Merz received an equity award of 1,573 shares of Common Stock through restricted stock units. The grant was made at no cash cost to her and is a form of stock-based compensation rather than an open-market purchase.
Each RSU converts into one iRhythm share when it vests. The units vest on the earlier of one year after the grant date or the company’s next annual meeting. After this award, she directly holds 10,546 shares of iRhythm common stock.
Bodaken Bruce G. reported acquisition or exercise transactions in this Form 4 filing.
iRhythm Holdings director Bruce G. Bodaken received a stock-based award. He was granted 1,573 shares of common stock in the form of restricted stock units at no cash cost. Following this grant, he holds 14,211 shares directly. The RSUs vest on the earlier of one year after grant or the company’s next annual meeting.
iRhythm Holdings, Inc. director Karen Ling received an equity award in the form of restricted stock units. She acquired 1,573 shares of common stock at a grant price of $0.00 per share, increasing her direct holdings to 11,141 shares after the transaction.
The award consists of RSUs, each representing a contingent right to receive one share of iRhythm common stock. The RSUs vest on the earlier of one year after the grant date or the date of the company’s next annual meeting, tying the award to continued service on the board.
MCGINNIS KAREN K reported acquisition or exercise transactions in this Form 4 filing.
iRhythm Holdings, Inc. director Karen K. McGinnis received an equity grant of 1,573 shares of common stock in the form of restricted stock units (RSUs). The award was granted at no cash cost per share and is part of her director compensation.
Each RSU represents a contingent right to receive one share of iRhythm common stock. The RSUs vest on the earlier of one year after the grant date or the company’s next annual meeting. After this grant, McGinnis directly holds 3,608 shares of common stock.
OBOYLE KEVIN C reported acquisition or exercise transactions in this Form 4 filing.
iRhythm Holdings director Kevin C. O’Boyle received an equity grant of 1,573 restricted stock units. The RSUs were awarded at no cash cost and each unit represents a right to one share of iRhythm common stock. The award vests on the earlier of one year after grant or the company’s next annual meeting. Following this grant, O’Boyle directly holds 3,608 shares.
TALWALKAR ABHIJIT Y reported acquisition or exercise transactions in this Form 4 filing.
iRhythm Holdings, Inc. director Abhijit Y. Talwalkar received a grant of 1,573 shares in the form of restricted stock units. Each RSU represents a contingent right to receive one share of iRhythm common stock. The RSUs vest on the earlier of one year after grant or the company’s next annual meeting, bringing his direct holdings to 21,872 shares.